Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell ...

Study does deep dive on if refs are favoring Chiefs in biggest games — here’s what researchers found

Research conducted recently by the University of Texas at El Paso (UTEP), a public research university, suggests that what we are seeing on screen isn’t an anomaly or your imagination: The Chiefs are ...